Chromatographic evaluation of the influence of ostarine and ecdysterone on male and female steroid profiles
Abstract
Selective androgen receptor modulators belong to a new class of doping agents which significantly increase the performance of athletes without the characteristic side effects of anabolic-androgenic steroids. There are now a number of methods used to identify these modulators in human biological fluids. However, there is practically no information about the way they affect the steroid profile. The article describes the in-fluence of ostarine usage on steroid profiles of men and women. The research was based on the qualitative and quantitative analysis of more than 10 thousand urine samples free from WADA prohibited compounds, performed in order to obtain a statistically significant representative sampling, as well as the analysis of 17 female and 13 male ostarine (or its metabolites) positive samples, and 532 male and 245 female ecdysterone positive samples. The quantification of the androgenic steroids was performed by means of gas chromatog-raphy (a validated technology) coupled with tandem mass spectrometric detection in the multiple reaction monitoring mode after derivatisation of the samples with the mixture of dithiothreitol, ammonium iodide, and N-Methyl-N-(trimethylsilyl)trifluoroacetamide. The study demonstrated a significant change in the number of androgenic steroids in female urine after ostarine administration, while in male urine samples this effect was not observed. The use of ecdysterone doesn’t significantly affect the content of androgenic steroid hor-mones in either men or women. Based on the analysed samples that were free from WADA prohibited com-pounds, we suggest stricter limitations on the content of androgenic steroids for females, which don’t lead to a significant increase in the number of false positive results. The approach allows us to obtain additional indi-rect signs indicating the possibility of an athlete using prohibited substances without resorting to additional procedures and studies. Suspicious or presumably positive samples can be tested in further studies. Such an integrated approach will significantly increase the reliability of studies and enhance the detection of positive samples without increasing the time and cost of the analysis
Downloads
References
Davey R.A., Grossmann M., Clin. Bio-chem., 2016, Vol. 37, pp. 3-15.
McEwan I.J., Future Med. Chem., 2013, Vol. 5, pp. 1109-1120. DOI: 10.4155/fmc.13.69
Gao W., Dalton J.T., Drug Discov. Today, 2007, Vol. 12, pp. 241-248. DOI: 10.1016/j.drudis.2007.01.003
Kim J., Wang R., Veverka K.A., Dalton J.T., Xenobiotica, 2013, Vol. 43, pp. 993-1009. DOI: 10.3109/00498254.2013.788233
Kintz P., Ameline A., Gheddar L., Raul J.-S., Toxicologie Analytique et Clinique, 2019, Vol. 31, pp. 56-63. DOI: 10.1016/j.toxac.2018.12.001
de Rijkea E., Essersa M.L., Rijka J.C.W., Thevis M., Boveea T.F.H. et al., Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess., 2013, Vol. 30, pp. 1517-1526. DOI: 10.1080/19440049.2013.81034
Thevis M., Schänzer W., Mol. Cell. Endo-crinol., 2018, Vol. 464, pp. 34-35. DOI: 10.1016/j.mce.2017.01.040
Thevis M., Thomas A., Fusshöller G., Beuck S. et al., Rapid Commun. Mass Spec-trom., 2010, Vol. 24, pp. 2245-2254. DOI: 10.1002/rcm.4637
Krug O., Thomas A., Beuck S., Schenk I. et al., Equine. Vet. Sci., 2012, Vol. 32, pp. 562-568. DOI: 10.1016/j.jevs.2012.01.005
WADA 2018 Anti-Doping Testing Figures Report. Available at: https://www.wada-ama.org/sites/default/files/resources/files/2018_testing_figures_report.pdf (accessed 30 May 2020)
WADA Athlete Biological Passport Oper-ating Guidelines. Available at: https://www.wada-ama.org/sites/default/files/resources/files/guidelines_abp_v71.pdf (accessed 30 May 2020)
Mohd Rodhia A., Abdul Latif M.N.F., Sal-ima S.A., Abdul Manaf N. et al., Sci. Sports., 2019, Vol. 34, pp. 52-55. DOI: 10.1016/j.scispo.2018.09.003
Häkkinen M.R., Heinosalo T., Saarinen N., Linnanen T. et al., J. Pharm. Biomed. Anal., 2018, Vol. 152, pp. 165-172. DOI: 10.1016/j.jpba.2018.01.034
Marta Z., Bobaly B., Fekete J., Magda B., et al., J. Pharm. Biomed. Anal., 2018, Vol. 150, pp. 258-267. DOI: 10.1016/j.jpba.2017.12.014
De Wilde L., Roels K., Van Renterghem P., Van Eenoo P. et al., J. Chromatogr. A, 2020, Vol. 1624, pp. 1-10. DOI: 10.1016/j.chroma.2020.461231
Iannone M., Palermo A., de la Torre X., Romanelli F. et al., Steroids, 2019, Vol. 152, 108491. DOI: 10.1016/j.steroids.2019.108491
Saad K., Vonaparti A., Athanasiadou I., Saleh A., et al., Steroids, 2019, Vol. 152, 108477. DOI: 10.1016/j.steroids.2019.108477.
Martín-Escudero P., Muñoz-Guerra J.A., García-Tenorio S.V., Garde E.S. et al., Steroids, 2019, Vol. 141, pp. 104-113. DOI: 10.1016/j.steroids.2018.11.009
Wang J., Wu M., Liu X., Xu Y., Steroids, 2011, Vol. 76, pp. 1560-1565. DOI: 10.1016/j.steroids.2011.09.007
Prasolov I.S., Diss. cand. him. nauk, Mo., 2015, 166 p.
Kochnova E.A. Diss. cand. him. nauk, M., 2012, 169 p.
Tsitsimpikou C., Tsamis G.D., Siskos P.A., Spyridaki M.H. et al, Rapid Commun. Mass Spectrom., 2001, Vol. 15, pp. 1796-1801. DOI: 10.1002/rcm.433
Parr M.K., Ambrosio G., Wuest B., Mazza-rino M. et al., Forensic Toxicol., 2020, Vol. 38, pp. 172-184. DOI: 10.1007/s11419-019-00504-y
Destrez B., Pinel G., Monteau F., Lafont R. et al., Anal. Chim. Acta, 2009, Vol. 637, pp. 178-184. DOI: 10.1016/j.aca.2008.10.015
WADA The 2020 Monitoring Program. Available at: https://www.wada-ama.org/sites/default/files/wada_2020_english_monitoring_program_.pdf (accessed 30 May 2020)
WADA Technical Document – TD2015IDCR. Available at: https://www.wada-ama.org/sites/default/files/resources/files/td2015idcr_-_eng.pdf (accessed 30 May 2020)
